- GNQ Insilico's ("GNQ") proprietary genomics-driven platform is leveraging Artificial Intelligence (AI) and Quantum Computing technologies to create "intelligent digital twins" of human patients that can mimic how a drug will interact with an individual patient's unique biology, down to the cellular level. - GNQ's platform has demonstrated success in synthesizing digital twins of human patients. - Additionally, GNQ was able to simulate the effects of a ...
[ more ]
